Search

In this paper, we propose the application of strategic analysis tools to design an educational program. Findings are based on the case of the Master in Innovative Manufacturing Systems (MIMS), a unique training offer to achieve a multidisciplinary expertise in smart manufacturing, in a two-year program simulating the journey of innovation. Building on novel educational paradigms and recent developments in the area of manufacturing, the main goal of the program is to provide the European industry with outstanding experts willing, able, and trained to bring novel solutions that address relevant societal challenges. Special emphasis is placed on real-world contexts and proactive activities, as well as strategies to continuously update the program. We aim to contribute to the educational facet of smart manufacturing. [ABSTRACT FROM AUTHOR]

Background: Recent research has focused attention on social cognition impairment in Alzheimer Disease (AD). Specifically, emotion recognition can be evaluated with Reading the Mind in the Eyes Test (RMET). Some neuroanatomical changes could be related with social and cognitive deficits in patients. Therefore, future research combining cognitive indicators (RMET) with brain structure and function parameters (volumes, glucose metabolism, blood flow, amyloid deposits...) is required. Method: Participants are patients from the Neurology Unit (Hospital Universitari i Politècnic La Fe). They were neuropsychologically evaluated, and CSF samples were obtained to determine some biomarkers (β‐amyloid‐42, β‐amyloid‐40, p‐Tau...). Also, brain imaging techniques (magnetic resonance (MR) and Positron Emission Tomography with [18F]Fluorodeoxyglucose (FDG‐PET/CT)) were applied to obtain brain structural and functional information, and to evaluate the relationship between them and emotion recognition evaluation (RMET). Imaging data were processed following SPM and CAT12 pipelines, a brain parcellation based on the Hammers atlas was used. Finally, 166 patients (with MR and/or FDG‐PET/CT) diagnosed with mild cognitive impairment (MCI) were included in the study. Result: The correlation analysis between FDG‐PET/CT and RMET results showed significant correlations. Specifically, with prefrontal medial L and R (r = 0.36), posterior cingulate L and R (r = 0.34), parietal inferior L and R (r = 0.31), anterior cingulate L and R (r = 0.32), prefrontal lateral L and R (r = 0.32), insula R (r = 0.31) and basal ganglia R (r = 0.3). So, they are considered potential brain function biomarkers in MCI. Regarding the correlation analysis between MR (GM volumes (TIV‐corrected)) and RMET results, some significant correlations were observed. Specifically, with the straight gyrus L (r = 0.40), superior frontal gyrus L (r = 0.37), insula anterior inferior cortex R (r = 0.36), fusiform gyrus R (r = 0.36), anterior cingulate gyrus R (r = 0.36), insula anterior short gyrus L (r = 0.36), posterior and anterior cingulate gyrus L (r = 0.36, 0.35), and anterior orbital gyrus L (r = 0.35). So, they are considered potential brain structure biomarkers in MCI. Conclusion: The relationship between brain imaging parameters and emotion recognition impairment variables could provide important information for further biomarkers identification, as well as to identify potential physiopathological mechanisms involved in neurodegenerative development since early steps. [ABSTRACT FROM AUTHOR]

Background: The Valencian Cognitive Diseases Study (VALCODIS) provides a large cohort of cases suffering from neurodegenerative diseases causing cognitive problems in their initial phases. This cohort is being obtained from admitted patients at Cognitive Disorders Unit Hospital Universitari i Politècnic La Fe (Valencia, Spain), as a basis to contribute on the Alzheimer's disease (AD) diagnosis and prognosis research. Method: Patients who come to the Cognitive Disorders Unit at Neurology Department of Hospital La Fe can be recruited to the VALCODIS cohort after their informed consent have been obtained. Patients with moderate and severe dementia are not proposed to participate. Included patients were studied with standard analytical and neuroimaging procedures, commonly brain MR, and CSF biomarkers determination (β‐amyloid‐42, β‐amyloid‐40, p‐Tau, t‐Tau, neurofilament light chain). Patients on anticoagulation, other contraindications or not suitable for LP can be included if an amyloid brain PET can be obtained. In some patients, brain PET with FDG is also obtained. After amyloid status is assured, a detailed neuropsychological evaluation is obtained in every patient using at least MMSE, CDR, RBANS and GDS scales. Finally, blood samples were taken to determine some potential biomarkers (lipid peroxidation, lipids, proteins, microRNAs) and stored simultaneously with CSF samples. Result: A total of 1100 participants aged 50 to 80 years, who were on follow up from January 2017 to August 2022 have been included in the VALCODIS cohort. This cohort is composed by early AD patients (mild cognitive impairment (MCI), mild dementia), other dementias in their initial phases (frontotemporal dementia, Lewy body dementia, vascular dementia) and cognitively healthy persons. Also, some of MCI‐AD patients were followed‐up at 2 years to carry out a prognosis study, by means of neuropsychological evaluation and blood biomarkers. Conclusion: The VALCODIS cohort represents a valuable infrastructure describing 6‐year experience about early and specific AD diagnosis, and prognosis. This cohort will provide a large number of patients, biologically diagnosed by CSF biomarkers, as well as their demographical, clinical and biochemical data. In addition, the biological samples (blood, plasma, urine, saliva, CSF) were stored to carry out further biomarkers studies. [ABSTRACT FROM AUTHOR]